Skip to main content
. 2021 Oct 30;23:524–538. doi: 10.1016/j.omtm.2021.10.011

Figure 4.

Figure 4

Cohort of 7 SMA patients receiving onasemnogene abeparvovec early in life

Longitudinal plots for pNf-H concentrations, Nf-L concentrations, and CMAP values for each individual case (A–G) in this cohort. Arrows indicate the onasemnogene abeparvovec injection time point for each case.